ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Account Active
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / MRKR / dividends
AEON (46) NEUP (31) RADX (46) PBM (46) ⌘ Pro Terminal β†’

Marker Therapeutics Inc. (MRKR) Dividend Safety Gauge & 10-Year DRIP Compounder

$0.90 -8.05% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.89

Marker Therapeutics Inc. (MRKR) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $16.3M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MRKR Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is MRKR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Marker Therapeutics Inc. (NASDAQ: MRKR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.90 (-8.05% 1D, market cap $16.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, MRKR ranks #610 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does MRKR compare to AEON and NEUP in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MRKR carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, AEON (AEON Biopharma Inc. (Class A)) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $16.2M) and NEUP (Neuphoria Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -11.8%, cap $16.5M). Among the 5-stock peer group, MRKR leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MRKR?
β–Ό

Per MRKR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001094038), Marker Therapeutics Inc. generated $36.1M in revenue (+15.9% YoY), -$12.2M in net income, and -$12.0M in free cash flow against $19.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.89 (-1.64%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 7/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (35/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510035
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk D
Cash (7)Whales (5)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10% Base Target
$3 Bull$1 Base$1 Bear
πŸ“¬ FREE MRKR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for MRKR)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
πŸ” WHY MRKR SCORES 35/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 2/9

β–² #2 Bullish Driver: Macro Regime Fit+8/20 pts (23% of score)

FRED Regime Γ— Technicals: 4% of 52W Range β€’ RSI-14 at 45 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
43
Grade D$0.92+26.1% Next Q
Q2 (-2Q)
40
Grade D$1.16-18.1% Next Q
Q3 (-1Q)
38
Grade E$0.95-5.3% Next Q
Current
35
Grade D-$0.90-8.5% Hist 90D Ξ±
Trajectory: D (43) β†’ D- (35)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a MRKR Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While MRKR currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.13) and Max Pain ($0.95) forces dealer call-delta covering toward $2.58.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MRKRβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œMRKR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 35%NO 65%Trade / Inspect Odds β†’
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 β€’ REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years β†’ $19,307

Est. Year-10 Shareholder Yield: $348/yr
$10.7K
Yr 1
$11.4K
Yr 2
$12.2K
Yr 3
$13.0K
Yr 4
$13.9K
Yr 5
$14.8K
Yr 6
$15.8K
Yr 7
$16.9K
Yr 8
$18.1K
Yr 9
$19.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MRKR)

  • βœ“Walkthrough of MRKR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
MRKR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -42.31%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $1.01H $1.01L $0.90C $0.90VOL 67.6K
RES: $1.43SUP: $0.82SMA50: $1.13SMA200: $1.36
$1.78$1.53$1.29$1.04$0.79RES $1.43SUP $0.82$0.902026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MRKR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ MRKR Butterfly Map β†’ + Track MRKR β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +15.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MRKR today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for MRKR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MRKR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MRKR)

Health Care Rank #610 of 1015 βš”οΈ AEON vs MRKR Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (MRKR vs. AEON, NEUP, RADX, PBM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Marker Therapeutics Inc. (MRKR) ranks #610 by composite RQD confidence (35/100, grade D-) and #844 by equity capitalization ($16.3M). Within this direct 5-issuer industry benchmark cohort, MRKR leads on earnings valuation at N/A trailing P/E, while NEUP leads on capital efficiency and profitability with -11.8% ROIC and β€” gross margin. AEON currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with MRKR at 35/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MRKR ACTIVE
Marker Therapeutics Inc.
D- 35/100 β€” β€” -35.0% -8.05% $16.3M Benchmark Subject
AEON
AEON Biopharma Inc. (Class A)
D 46/100 β€” β€” -35.0% -0.36% $16.2M /aeon-vs-mrkr β†’
NEUP
Neuphoria Therapeutics Inc.
E 31/100 β€” β€” -11.8% -0.33% $16.5M /neup-vs-mrkr β†’
RADX
Radiopharm Theranostics Limited
D 46/100 β€” β€” β€” -8.05% $15.6M /radx-vs-mrkr β†’
PBM
Psyence Biomedical Ltd.
D 46/100 β€” β€” β€” -3.93% $17.6M /pbm-vs-mrkr β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001094038 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Marker Therapeutics Inc. (MRKR) reported GAAP revenue of $36.1M (+15.9% vs. FY2024 revenue of $31.1M , and -11.6% cumulative change since FY2023) , GAAP net income of -$12.2M, operating cash flow of -$12.0M, and free cash flow of -$12.0M (-10.1% YoY). On the balance sheet, MRKR closed FY2025 with $19.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $36.1M -$12.2M -$12.0M -$12.0M $19.1M β€”
FY2024 (FY) 2024-12-31 $31.1M -$10.7M -$10.9M -$10.9M $22.0M β€”
FY2023 (FY) 2023-12-31 $40.8M -$8.2M -$16.4M -$16.4M β€” β€”

3. MRKR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MRKR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Marker Therapeutics Inc. (NASDAQ: MRKR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.90 (-8.05% 1D, market cap $16.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, MRKR ranks #610 in composite RQD confidence.

How does MRKR compare to AEON and NEUP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MRKR carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, AEON (AEON Biopharma Inc. (Class A)) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $16.2M) and NEUP (Neuphoria Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -11.8%, cap $16.5M). Among the 5-stock peer group, MRKR leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MRKR?

Per MRKR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001094038), Marker Therapeutics Inc. generated $36.1M in revenue (+15.9% YoY), -$12.2M in net income, and -$12.0M in free cash flow against $19.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MRKR trading relative to its 50-day, 200-day, and 52-week technical levels?

MRKR last traded at $0.90 (-8.05% on volume of 265,722 shares), positioning the stock -20.35% below its 50-day simple moving average ($1.13) and -33.82% below its 200-day simple moving average ($1.36). Across its 52-week range of $0.84 to $2.46, MRKR sits at the 3.7% percentile with a 14-day RSI of 45.0 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.00 to $1.01).

Direct Sub-Reports: MRKR RQD Cockpit MRKR 12M Forecast MRKR Earnings & Move MRKR Dividends & DRIP MRKR Insiders & 13F MRKR Whale Options MRKR Profit Sankey MRKR News & Why
ROARABLE RATING BRIEF β€’ RQD 35/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

MRKR β€” Marker Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Marker Therapeutics Inc. (MRKR) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.90 (-8.05% 1D, market capitalization $16.3M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of β€”, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Marker Therapeutics Inc. (MRKR) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It is a biotechnology company. Specific products, customers, and revenue model details are β€” Reported revenue across the financial periods is β€”.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Marker Therapeutics Inc. (MRKR) reported $36.1M in annual revenue (up from $31.1M in FY2024, +15.9% YoY) and -$12.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($40.8M revenue, -$8.2M net income) through FY2025, MRKR scaled operating cash flow to -$12.0M and free cash flow to -$12.0M, backed by $19.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 5/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.84 – $2.46 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), MRKR carries a macro regime beta of 1.00 and gross margin of β€”.

  • Key Question #1: Can MRKR sustain or expand its β€” operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $36.1M and free cash flow of -$12.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is MRKR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MRKR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Marker Therapeutics Inc. (MRKR) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to MRKR Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MRKR Bull vs. Bear Conversation Board β€” What's Your Call at $0.90?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MRKR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MRKR:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER β€’ Swing & Catalyst Trader πŸ‚ BULLISH 🎯 Target: $1.27 (+29.6%)
πŸ“Œ Pinned Debate

Market-wire coverage includes a rating-upgrade headline to Strong Buy, and the stock trades near its 52-week low at $1.01 versus a $2.4

Here is why I am bullish on MRKR here at $0.98: Market-wire coverage includes a rating-upgrade headline to Strong Buy, and the stock trades near its 52-week low at $1.01 versus a $2.46 high.. Compare MRKR's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $0.93 are getting bought.

EarningsSniper πŸ‚ BULL

@SkepticalCFA Shorting a 5/20 institutional whale-flow stock at $0.98 is dangerous when funds are rotating into Health Care.

SK SkepticalCFA RQD DEBATE OPENER β€’ Fundamental Contrarian 🐻 BEARISH 🎯 Target: $0.73 (-25.5%)
Spot @ $0.98

With zero revenue, a -35% ROIC, a Piotroski F-Score of 2/9, and cash falling from $19.2M to $16.1M, the company shows no visible path t

Careful chasing MRKR at $0.98. With zero revenue, a -35% ROIC, a Piotroski F-Score of 2/9, and cash falling from $19.2M to $16.1M, the company shows no visible path to self-funded operations.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $0.73 on multiple compression.

LIVE TAPE